Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Introduction to Hemostasis01:05

Introduction to Hemostasis

15.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
15.2K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

14.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.0K
Coagulation01:09

Coagulation

11.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.2K
Coagulation01:06

Coagulation

1.5K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.5K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

10.4K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
10.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Platelet-activating histone/antihistone IgG complexes in anti-PF4-negative thrombosis and thrombocytopenia syndrome.

Blood advances·2025
Same author

Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report.

Therapeutic advances in hematology·2022
Same author

High SARS-CoV-2 vaccination coverage but still room for improvement in patients with haemophila: A single-centre analysis.

Haemophilia : the official journal of the World Federation of Hemophilia·2022
Same author

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors.

Blood advances·2021
Same author

Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events.

Blood advances·2021
Same author

Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures.

Therapeutic advances in hematology·2021

Related Experiment Video

Updated: Feb 26, 2026

Author Spotlight: Revealing Platelet Dynamics Through Advances in Structural Hematology
05:41

Author Spotlight: Revealing Platelet Dynamics Through Advances in Structural Hematology

Published on: May 24, 2024

682

ASH Meeting 2016: developments in hemostaseology.

Clemens Feistritzer1, Birgit Mosheimer2

  • 1Internal Medicine V - Hematology and Oncology, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck (Tyrol), Austria.

Memo
|July 21, 2017
PubMed
Summary

Gene therapy using adeno-associated virus showed success in hemophilia B patients, offering an alternative to factor replacement. Other advancements included bispecific antibodies for hemophilia A and new anticoagulation strategies.

Keywords:
AnticoagulationAtrial fibrillationCancerGene transferHemophilia

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.2K
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

10.1K

Related Experiment Videos

Last Updated: Feb 26, 2026

Author Spotlight: Revealing Platelet Dynamics Through Advances in Structural Hematology
05:41

Author Spotlight: Revealing Platelet Dynamics Through Advances in Structural Hematology

Published on: May 24, 2024

682
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.2K
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

10.1K

Area of Science:

  • Hematology
  • Hemostasis
  • Gene Therapy

Background:

  • The American Society of Hematology (ASH) meeting is a key venue for presenting novel hemostaseology developments.
  • Traditional hemophilia treatment relies on factor replacement, but alternative strategies are being explored.

Purpose of the Study:

  • To review significant advancements in hemophilia treatment and anticoagulation presented at ASH 2016.
  • To highlight alternative therapeutic approaches beyond factor replacement for hemophilia patients.

Main Methods:

  • Review of presentations from the American Society of Hematology (ASH) 2016 annual meeting.
  • Focus on gene therapy, bispecific antibodies, and direct oral anticoagulants (DOACs).

Main Results:

  • Successful adeno-associated virus-mediated gene transfer in hemophilia B patients led to sustained Factor IX:C elevation.
  • Alternative treatments for hemophilia A, including bispecific antibodies and disruption of anticoagulant proteins, were discussed.
  • Data on direct oral anticoagulants (DOACs) in cancer patients with atrial fibrillation and treatment of superficial vein thrombosis were presented.

Conclusions:

  • Gene therapy represents a promising alternative treatment for hemophilia B.
  • Advancements in bispecific antibodies and anticoagulation offer new therapeutic avenues for hemophilia A and related conditions.